Takeda CFO Says Midterm Strategy Not Affected by Halt of TAK-875 Trials

Takeda Pharmaceutical Chief Financial Officer François-Xavier Roger said on February 5 that the company’s midterm growth strategy through FY2017 will not be largely affected by the termination of the global development of its G protein-coupled receptor (GPR) 40 agonist TAK-875...read more